To screen for endogenous metabolites associated with JAK2, PV patients were divided into a JAK2-mutated group (n = 24) and a JAK2-unmutated group (n = 8) according to their JAK2 mutation status, and the PLS-DA model was used to represent the changes in metabolic profiles of patients in the JAK2-mutated and JAK2-unmutated groups. This evidence concerns the gene JAK2 and acquired polycythemia vera.